Bis-intercalating Peptide Conjugates for Targeted DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer and microbial infections lack effective agents that can specifically target and inhibit the proliferation of tumor, microbial, and viral cells while minimizing harm to healthy cells.
Innovation Solution
Development of bis-intercalating peptides and their conjugates, which are designed to bind DNA and exert cytotoxic effects on target cells, utilizing a cyclic peptidic scaffold and chromophores, and can be conjugated with targeting moieties like antibodies to enhance specificity and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat cancer and microbial infections, then broad-spectrum coverage is achieved, but specificity to target cells is reduced and harm to healthy cells increases
Solution Approach 1:
The patent employs targeting moieties (such as antibodies, peptides, or small molecules) as intermediaries that specifically bind to receptors or antigens on the surface of target cells (tumor, microbial, or viral cells). This intermediary binding ensures that the bis-intercalating peptide is delivered selectively to the intended target, thereby improving specificity and reducing off-target effects on healthy cells.
Solution Approach 2:
The invention creates a heterogenous structure where different parts of the conjugate have distinct functions: the targeting moiety provides cell-specific recognition and binding, while the bis-intercalating peptide core provides the cytotoxic effect. This local differentiation of function allows the therapy to act selectively on target cells while sparing healthy tissue.
2Reliability
If bis-intercalating peptides are conjugated with targeting moieties to enhance specificity, then targeted delivery is improved, but device complexity increases
Solution Approach 1:
The conjugate is divided into distinct functional segments: a targeting moiety segment and a bis-intercalating peptide core segment. This segmentation allows each component to be optimized independently for its specific function while maintaining overall conjugate stability and efficacy.
Solution Approach 2:
The invention creates a composite structure by chemically conjugating the targeting moiety with the bis-intercalating peptide core through suitable linkers. This composite material combines the specific binding properties of the targeting moiety with the potent cytotoxic activity of the peptide core, achieving both targeted delivery and therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bis-intercalating peptides and their conjugates effectively inhibit the proliferation of tumor, microbial, and viral cells, offering a potential therapeutic approach for cancer and microbial infections with targeted specificity and reduced toxicity to healthy cells.
Implementation Method 1
two planar heteroaromatic units, or 'chromophores,' which bind to duplex DNA by bis-intercalation
Data Source
AI summary
Bis-intercalating peptide compounds having Formula I, which are capable of binding DNA and exerting a cytotoxic effect on cells, such as microbial, viral or tumour cells, and conjugates comprising the compounds linked to a targeting moiety, such as an antibody. The compounds and conjugates may be used in the treatment of cancer or a microbial or viral infection, or as diagnostic agents or labelling agents.